-
BeiGene Prices TEVIMBRA 10% Below Competitors Following FDA Approval for Esophageal Cancer Treatment
•
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the commercial availability of TEVIMBRA (Tislelizumab) in the United States following its approval by the FDA for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy. The drug received FDA approval in March…
-
Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award
•
China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year’s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm’s Q3 earnings conference call. The FasTCAR platform enables the “next-day manufacture” of autologous chimeric antigen receptor…
